{
    "organizations": [],
    "uuid": "06d4eb1b78448496acbbc632d89baf7e7b1a4ed3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-horizon-pharma-plc-submits-supplem/brief-horizon-pharma-plc-submits-supplemental-nda-for-ravicti-idUSFWN1QH1GT",
    "ord_in_thread": 0,
    "title": "BRIEF-Horizon Pharma PLC Submits Supplemental NDA For Ravicti",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Horizon Pharma Plc:\n* HORIZON PHARMA PLC SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR RAVICTIÂ® (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID TO EXPAND AGE RANGE TO INCLUDE NEWBORNS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T01:14:00.000+02:00",
    "crawled": "2018-02-28T01:34:48.034+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "horizon",
        "pharma",
        "plc",
        "horizon",
        "pharma",
        "plc",
        "submits",
        "supplemental",
        "new",
        "drug",
        "application",
        "glycerol",
        "phenylbutyrate",
        "oral",
        "liquid",
        "expand",
        "age",
        "range",
        "include",
        "newborn",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}